Introduction
Tn vitro-in vivo con-eialion (IVIVC) has been defined by the 
Rationale of IVIVC I t is generally easier to estab lis h h ig her leve ls of
Ivrvc with control ledre lease dosage forms than with im mediate-release dosage fo rms. W ith controll ed-release formu lations, dissolu tion (or re lease fro m the form ul atio n) tends to be the rate-limiti ng step in the absorption process. Beca ll se d iffere n t con tro ll edre lease products generally emp loy d iffere n t controlledre lease mechan isms, it must be emphasized that IVIVCs for controlled-release form ulations must be considered to be product-specific (7). Each formu lation development effort for a new drug must be treated on a case-by-case basis.
NIVC for controll ed-release dosage forms will be of benefit to a company when regulatory authorities permit it to be utilized in one or more of the fo llowing ways:
• surrogate to bioequivalency studies which migh t typica ll y be required with sca le-up or minor post-approva l cha nges (SUPAC);
• va lidate the LIse of dissolution testing and specifications as a qua lity contro l tool for process contro l; disso lutio n specifications in qua lity control ra nges may be shown to be relevant to in vivo data;
• identity appropriate dissolution condjtions for a forrnuJation whjch resu lt in data relevant to in vivo performance;
• predict in vivo performance of a formu lation based on in vitro dissolution data, whic h may aid in the design of formulation release-time profi les resu lti ng in optimal plasma concentration-time profi l~s.
Levels of In Vitro-In Vivo Correlation
W ith respect to t h e FDA definition of NIVC, dissolution data provide in vitro data for a dosage form and plasma drug concentration-time data are deconvoluted (see fol lowing section) to provide an estimate of absorption data for the same dosage form. The following degrees of corre latio n of in vitro with in vivo data have been established and accepted in the literature fo r controll edrelease ora l dosage forms (1, 4, 8, 9 however, a rank-order re lationship alone might be considered a low Level C correlation and would be of a qualitative nature.
Mapping
It has been suggested that "mapping" be used as an alternative to seeking an IV1VC (5) . 
Deconvolution and Convolution
Scbemc I summarizes the re lationships of deconvolution or convolution to NNe. Based Alternately, a knowledge of the pharmacokin etics of a drug lTIay be combined with, or convoluted with, the dissolutiontime profil e of an oral dosage form to simulate a plasma concentration-time profil e for administration of the controlled-release dosage form to man (Scheme J). Leeson 
on a knowledge of the pharma--------------cokineti c sys-

Artificial Neural Networks
In the last ten years, applica- 
Practical Approach to the level A In Vitro-In Vivo Correlation
The Level A correlation is currentl y the high est level of IVTVC recogn ized and may be speci fi ed as a requirement when addressing SUPAC issues without bioequivalency data. The following approaches and examples are meant to demonstrate a starting point for investigation of a Level A correlation.
Qualitative:
The first test of a Level A Figure J demonstrates the correlation at a qualjtative level.
Quantitative:
Linear relationship of absorption /IS fI function of dissolution Using x-y data pairs representing estimates of dissolution and absorption at common time points, linear regression is performed. By far, this appears to be one of the more popular methods that many researchers use initially to investigate a quantitative relationship between dissolution and absorption data. Superimposable data will have a one-to-one relatiOl~ and a linear relationship with a slope of one, an intercept of zero, and a coefficient of determination (r-squared) of one. It has been suggested that a y-intercept less than zero might be explained by a lag-time in absorption, whereas a significant positive y-intercept would not make sense (2). Ideally, the dissolution and absorption data used with this approacb should be derived from an adequate number of data points such that each process is fully profiled. Linear regression of the dissolution and absorption data in Figzn-e I at conunon tUne points was perfonned.
Hwang et al. (15) vivo dissolution-time data were estimated using numerical deconvolution methods (12 , 13) . In cases where drug-release is constant (zero-order), then a simple time-shift in the absorption-time profile, equivalent to the reciprocal of the first-order absorption rate constant, may be used to establish a higher quality Level A correlation (15) . When drug release is a slow first-order process, the same approximation appears to apply.
T h e negatjve y-intercept for the linear regression in Figu1"e I is indicative of an overall trend for a lag of absorption relative to dissolution data_
Non-linear relationship of absorption (IS /I junction of dissolution
There are a variety of possibilities in which non-linear functions may be investigated and the utility of this approach appears to be somewhat empiricaL For example, with a nonlinTime (hr) Figure I ear relationship, there may be no parameter targets, analogous to that of linear relationshjps. And, it is somewhat conunon to observe some degree of curvature in a plot of absorption versus dissolution at common time points. Some examples of functions that might be used in thjs case include polynomial equations, Emax (16) and Weibull (17) type equations, and exponential or Gompertz equations (18) . The same djssolution and absorption data from Figure 1 was evaluated using a thirdorder polynomial equation.
Rescigno Index
It has been suggested by Dr. ] . Powers (18) 
Setting Dissolution Specifications
With controlled-release for- Contro ll ed-re lease formulations that are se n sitive to changes in the dissolution environment should be examined to determine in vitro conditions which achieve an optima l IV1VC (5). In this instance the dissolution scientist may playa major role in the optimization of all rvrvc.
Consensus indicates that the
hi stori ca ll y-based average dissolution data, plus or minus some measure of variation, has been genera ll y used to set disso lution specificatio n s (2 1).
Experience has demonst.rated
that the average ± up to 3 
Validation of IVIVC supporting dissolution specifications
Curre ntly, validation of an TVIVC appea r s to be moving toward the ability to d emonstrate that formulation s manufactured at th e limi ts of dissolution specifications must individually be s how n to be bioequivalent to a fo rmulation representing the mid-po int o f the disso luti on specification .
T h e co nce pt of a Leve l A correlatio n wou ld app ly and it would pro babl y be ex pected that there is some control over th e ability to manufacture formulation s with re lease rates correspo nding to the range of dissoluti o n speci fi cations.
Concluding remarks
Applicability o f IVTVC to SUPAC situations has currentJy evolved to include demonstration of a relationship of dissolution release specifications, based o n va riation in disso lution, to variation in phlsma conce ntrati o ns resulting from administration of th e same controll e d-re lease formu lation. Ideall y, an NIVC should try to demo nst rate ::1 re lation s hip between c riti ca l formulation param ete rs and dosage form performance, in vitro and in vivo. The prospect of using an TVtVC correlation as a surroga te for a bioequiva lency study appears to be a worthwhi le endeavor, as it would have the po te ntial to save tim e and money. However, investigation a nd use of IVIVC s h ou ld be viewed as a long-te rm investme nt in the business of drug deve lo pmen t.
